Cargando…

Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial

BACKGROUND: Patients with recurrent glioblastoma (rGB) have a poor prognosis with a median overall survival (OS) of 30–39 weeks in prospective clinical trials. Intravenous administration of programmed cell death protein 1 and cytotoxic T-lymphocyte-associated antigen 4 inhibitors has low activity in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Duerinck, Johnny, Schwarze, Julia Katharina, Awada, Gil, Tijtgat, Jens, Vaeyens, Freya, Bertels, Cleo, Geens, Wietse, Klein, Samuel, Seynaeve, Laura, Cras, Louise, D’Haene, Nicky, Michotte, Alex, Caljon, Ben, Salmon, Isabelle, Bruneau, Michaël, Kockx, Mark, Van Dooren, Sonia, Vanbinst, Anne-Marie, Everaert, Hendrik, Forsyth, Ramses, Neyns, Bart
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231061/ https://www.ncbi.nlm.nih.gov/pubmed/34168003 http://dx.doi.org/10.1136/jitc-2020-002296

Ejemplares similares

Intratumoral Combinatorial Administration of CD1c (BDCA-1)(+) Myeloid Dendritic Cells Plus Ipilimumab and Avelumab in Combination with Intravenous Low-Dose Nivolumab in Patients with Advanced Solid Tumors: A Phase IB Clinical Trial
por: Schwarze, Julia Katharina, et al.
Publicado: (2020)

Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx)
por: Awada, Gil, et al.
Publicado: (2020)

Low-Dose Bevacizumab for the Treatment of Focal Radiation Necrosis of the Brain (fRNB): A Single-Center Case Series
por: Tijtgat, Jens, et al.
Publicado: (2023)

Intratumoral administration of CD1c (BDCA-1)(+) and CD141 (BDCA-3)(+) myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial
por: Schwarze, Julia Katharina, et al.
Publicado: (2022)

A Phase 2 Clinical Trial of Trametinib and Low-Dose Dabrafenib in Patients with Advanced Pretreated NRAS(Q61R/K/L) Mutant Melanoma (TraMel-WT)
por: Awada, Gil, et al.
Publicado: (2021)

A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab
por: Awada, Gil, et al.
Publicado: (2021)

Durable Complete Response of a Recurrent Mesencephalic Glioblastoma Treated with Trametinib and Low-Dose Dabrafenib in a Patient with Neurofibromatosis Type 1
por: Awada, Gil, et al.
Publicado: (2020)

Neuro-oncological augmented reality planning for intracranial tumor resection
por: Van Gestel, Frederick, et al.
Publicado: (2023)

Early Reassessment of Total Metabolic Tumor Volume on FDG-PET/CT in Advanced Melanoma Patients Treated with Pembrolizumab Predicts Long-Term Outcome
por: Vermeulen, Sim, et al.
Publicado: (2021)

Focal radiation necrosis of the brain in patients with melanoma brain metastases treated with pembrolizumab
por: Du Four, Stephanie, et al.
Publicado: (2018)

Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial
por: Schwarze, Julia Katharina, et al.
Publicado: (2022)

S43. Dendritic cell vaccination combined with CTLA4 blockade
por: Thielemans, K, et al.
Publicado: (2014)

Overcoming the immune suppressive nature of glioblastoma by leveraging the surgical intervention - current status and future perspectives
por: Duerinck, Johnny, et al.
Publicado: (2023)

An Observational Study of the First Experience with Bevacizumab for the Treatment of Patients with Recurrent High-Grade Glioma in Two Belgian University Hospitals
por: Huylebrouck, M., et al.
Publicado: (2012)

Interpreting the impact of noncoding structural variation in neurodevelopmental disorders
por: D’haene, Eva, et al.
Publicado: (2020)

Long-Term Survival, Quality of Life, and Psychosocial Outcomes in Advanced Melanoma Patients Treated with Immune Checkpoint Inhibitors
por: Rogiers, Anne, et al.
Publicado: (2019)

Pituitary carcinoma - case series and review of the literature
por: Du Four, Stephanie, et al.
Publicado: (2022)

Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells
por: Tijtgat, Jens, et al.
Publicado: (2021)

Spreading Pattern and Tissue Response to Hyaluronic Acid Gel Injections in the Subcutis: Ultrasound Videos, Ultrasound Measurements, and Histology
por: Vandeputte, Joan, et al.
Publicado: (2020)

Symptomatic Histologically Proven Necrosis of Brain following Stereotactic Radiation and Ipilimumab in Six Lesions in Four Melanoma Patients
por: Du Four, Stephanie, et al.
Publicado: (2014)

Fasting, food and farming: Value chains and food taboos in Ethiopia
por: D’Haene, Eline, et al.
Publicado: (2021)

Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy
por: Seremet, Teofila, et al.
Publicado: (2019)

Low grade malignant eccrine spiradenoma of the vulva: case report, review of the literature and discussion about the role of p53 and HPV
por: Catteau, Xavier, et al.
Publicado: (2020)

Mimicking and anticipating others’ actions is linked to Social Information Processing
por: Genschow, Oliver, et al.
Publicado: (2018)

PIK3CA and p53 Mutations by Next Generation Sequencing in Lymphoepithelioma-Like Carcinoma of the Endometrium
por: Bienfait, Lucie, et al.
Publicado: (2018)

Osseous Metaplasia in Low-grade Ovarian Serous Carcinoma With a BRAF Mutation: A Case Report
por: Catteau, Xavier, et al.
Publicado: (2021)

Whole-Body MRI for the Detection of Recurrence in Melanoma Patients at High Risk of Relapse
por: Jansen, Yanina J. L., et al.
Publicado: (2021)

Patterns of Response in Patients with Pretreated Metastatic Melanoma who Received Ipilimumab 3 mg/kg in a European Expanded Access Program: Five Illustrative Case Reports
por: Wilgenhof, Sofie, et al.
Publicado: (2012)

Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies
por: Pombo Antunes, Ana Rita, et al.
Publicado: (2020)

First Report on Fetal Cerebral Polyglucosan Bodies in Mucopolysaccharidosis Type VII
por: Kadhim, Hazim, et al.
Publicado: (2017)

Comparison of excitation energy transfer in cyanobacterial photosystem I in solution and immobilized on conducting glass
por: Szewczyk, Sebastian, et al.
Publicado: (2016)

P53 and PIK3CA Mutations in KRAS/HER2 Negative Ovarian Intestinal-Type Mucinous Carcinoma Associated with Mature Teratoma
por: Bouri, Sarah, et al.
Publicado: (2020)

Religion, Food Choices, and Demand Seasonality: Evidence from the Ethiopian Milk Market
por: D’Haene, Eline, et al.
Publicado: (2019)

Invasive ductal carcinoma arising in borderline phyllode tumor: A potential role of PIK3CA mutation
por: Bouri, Sarah, et al.
Publicado: (2020)

First Case Report of a Uterine Angiolipoleiomyoma With KRAS and KIT Mutations
por: Verocq, Camille, et al.
Publicado: (2022)

Clinical Application of Targeted Next Generation Sequencing for Colorectal Cancers
por: Fontanges, Quitterie, et al.
Publicado: (2016)

Anti-NMDA-receptor encephalitis: an unusual treatable cause of chronic insomnia?
por: Wiels, Wietse A., et al.
Publicado: (2021)

Borderline phyllodes tumour of the breast with eosinophilic inclusion bodies: Case report and molecular sequencing
por: Lam, Ngoc My, et al.
Publicado: (2023)

Computer-vision based analysis of the neurosurgical scene – A systematic review
por: Buyck, Félix, et al.
Publicado: (2023)

GBM tumors are heterogeneous in their fatty acid metabolism and modulating fatty acid metabolism sensitizes cancer cells derived from recurring GBM tumors to temozolomide
por: Parik, Sweta, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_f786p8ras020o5mpcq31b09rjr